Zymeworks (ZYME) Projected to Announce Quarterly Earnings on Thursday

Zymeworks (NASDAQ:ZYME) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Zymeworks to announce earnings of ($0.5441) per share and revenue of $10.9060 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. The firm had revenue of $2.41 million during the quarter. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%. On average, analysts expect Zymeworks to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zymeworks Price Performance

NASDAQ:ZYME opened at $21.81 on Tuesday. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -15.92 and a beta of 1.15. Zymeworks has a one year low of $11.51 and a one year high of $29.75. The business has a fifty day moving average price of $24.15 and a 200-day moving average price of $24.47.

Zymeworks declared that its Board of Directors has initiated a share buyback plan on Thursday, May 14th that authorizes the company to buyback $125.00 million in shares. This buyback authorization authorizes the company to purchase up to 7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Institutional Trading of Zymeworks

Several hedge funds have recently made changes to their positions in ZYME. Quarry LP purchased a new position in shares of Zymeworks during the 3rd quarter worth about $50,000. Caitong International Asset Management Co. Ltd purchased a new stake in Zymeworks in the 4th quarter worth about $55,000. Tower Research Capital LLC TRC raised its position in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after purchasing an additional 1,131 shares during the period. BNP Paribas Financial Markets lifted its stake in Zymeworks by 157.7% in the second quarter. BNP Paribas Financial Markets now owns 10,307 shares of the company’s stock worth $129,000 after purchasing an additional 6,307 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in Zymeworks in the second quarter worth about $133,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZYME has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of Zymeworks in a report on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research report on Friday, July 17th. Truist Financial lifted their target price on shares of Zymeworks from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Citigroup reaffirmed a “buy” rating on shares of Zymeworks in a report on Tuesday, June 30th. Finally, Wells Fargo & Company raised their price target on Zymeworks from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zymeworks presently has an average rating of “Moderate Buy” and an average target price of $37.33.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.